Literature DB >> 27302119

Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply.

Orrin Devinsky1, Eric Marsh2, Daniel Friedman3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27302119     DOI： 10.1016/S1474-4422(16)00120-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  4 in total

Review 1.  Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.

Authors:  Brian Fiani; Kasra John Sarhadi; Marisol Soula; Atif Zafar; Syed A Quadri
Journal:  Neurol Sci       Date:  2020-06-16       Impact factor: 3.307

2.  Parasitic pharmacology: A plausible mechanism of action for cannabidiol.

Authors:  Geert Jan Groeneveld; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2019-07-10       Impact factor: 4.335

3.  Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany.

Authors:  Laurent M Willems; Astrid Bertsche; Frank Bösebeck; Frauke Hornemann; Ilka Immisch; Karl M Klein; Susanne Knake; Rhina Kunz; Gerhard Kurlemann; Lisa Langenbruch; Gabriel Möddel; Karen Müller-Schlüter; Felix von Podewils; Philipp S Reif; Bernhard J Steinhoff; Isabel Steinig; Felix Rosenow; Susanne Schubert-Bast; Adam Strzelczyk
Journal:  Front Neurol       Date:  2018-07-23       Impact factor: 4.003

4.  Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.

Authors:  Boudewijn Gunning; Maria Mazurkiewicz-Bełdzińska; Richard F M Chin; Hari Bhathal; Charlotte Nortvedt; Eduardo Dunayevich; Daniel Checketts
Journal:  Acta Neurol Scand       Date:  2020-10-22       Impact factor: 3.209
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.